The Effect of the Treatment by Combining Hyaluronic Acid (HA) Filler and Botulinum Toxin A (BTX-A) on the Upper Face

Authors

  • Gang-Ho Jong Researcher, Abdominal Surgical Department, Pyongyang Medical University, Pyongyang, Democratic People’s Republic of Korea.
  • Hak-Bom Han Researcher, Abdominal Surgical Department, Pyongyang Medical University, Pyongyang, Democratic People’s Republic of Korea.
  • Hui-Chol Kang Researcher, Abdominal Surgical Department, Pyongyang Medical College Hospital, Kim II Sung University, Korea.

Keywords:

Facial filler, Hyaluronic acid, Facial fold, Botulinum toxin, HA and BTX-A

Abstract

Context: Recently, more people have better aesthetic satisfactions with the application of various treatment methods. Especially, development of botulinum toxins and facial fillers provide patients having folds with new hopes. Aims: We studied to clarify the aesthetic effect of the treatment by combining the injectable hyaluronic acid (HA) and botulinum toxin A (BTX-A). Setting and designs: 115 patients complaining about folds in foreheads, glabellars, and lateral periorbital regions were selected. We made two groups; control group was treated only with injectable HA filler and experimental group by combining HA and BTX-A. Both groups were followed for 8 months after injection. Material and methods: HA (Restylane) and BTX-A were together applied to the upper face folds including forehead, glabellar and crow’s feet that were represented by mimetic muscles. We evaluated the correction and the maintenance effects in control and experimental groups at 0 and 8 months after treatments. Statistical analysis used: All the experimental values were analyzed statistically with Student’s t-test of Microsoft Excel 2013. Results: All the patients in both groups had efficient fold corrections, but there was no significant difference of the rate of maintenance between 2 groups. Conclusion: On the upper face, combined treatments with the injectable HA and BTX-A were intended to have better early effects than with only a filler, and the combined procedure didn’t have a significant difference in fold correction maintenance effects after 8 months.

References

Rzany B. Injectable Fillers in Aesthetic Medicine. Springer-Verlag Berlin Heidelberg 2006 Printed in Germany; 23–82pp.

Costa C. R, et al. Advances and Refinement in Hyaluronic Acid Facial Fillers, Plast Reconstr Surg. 2016; 138 (2); 233e-6.

Fabrizio Duranti, Giovanni Salti, Bruno Bovani, Mario Calandra, Maria Laura Rosati. Injectable Hyaluronic Acid Gel for Soft Tissue Augmentation. Inc Dermatol Surg. 1998; 24 (12); 1317–25.

Frampton JE. Botulinum Toxin A(Botox Cosmetic): A Review of its use in the Treatment of Glabellar Frown Lines. Am J Clin Dermatol. 2003; 4 (10): 709–25

Seth L. Matarasso, Jean D. Carruthers, Mark L. Jewell. Consesus Recommendation for Soft Tissue Augmentation With Stabilized Hyaluronic Acid (Restylane). Plast Reconstr Surg. 2006 Mar; 117 (3 Suppl): 3S–34S.

Sundaram H, Liew S, Signorini M, Vieira Braz A, Fagien S, Swift A et al. Global Aesthetics Consensus Hyaluronic Acid Fillers and Botulinum Toxin Type A-Recommendations for Combined Treatment and Optimizing Outcomes in Diverse Patient Populations. Plast Reconstr Surg. 2016; 137 (5); 1410–1423.

Wu WT, Liew S, Chan HH, Ho WW, Supapannachart N, Lee HK, et al. Consensus on Current Injectable Treatment Strategies in the Asian Face. Asian Facial Aesthetics Expert Consensus Group. Aesthetic Plast Surg. 2016; 40 (2); 202–14.

Downloads

Additional Files

Published

2022-02-21

Issue

Vol. 11 No. 1 (2022)

Section

Research Article

License

Declaration and Copyright Transfer Form

(to be completed by authors)

I/ We, the undersigned author(s) of the submitted manuscript, hereby declare, that the above manuscript which is submitted for publication in the STM Journals(s), is not published already in part or whole (except in the form of abstract) in any journal or magazine for private or public circulation, and, is not under consideration of publication elsewhere.

  • I/We will not withdraw the manuscript after 1 week of submission as I have read the Author Guidelines and will adhere to the guidelines.
  • I/We Author(s ) have neither given nor will give this manuscript elsewhere for publishing after submitting in STM Journal(s).
  • I/ We have read the original version of the manuscript and am/ are responsible for the thought contents embodied in it. The work dealt in the manuscript is my/ our own, and my/ our individual contribution to this work is significant enough to qualify for authorship.
  •  I/We also agree to the authorship of the article in the following order:

Author’s name                                    

 

1. ________________

2. ________________

3. ________________

4. ________________

 

We  Author(s) tick this box and would request you to consider it as our signature as we agree to the terms of this Copyright Notice, which will apply to this submission if and when it is published by this journal.